Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (December 2023)
30 slides from Prescient Therapeutics's investor presentation, Dec 18, 2023
Slide 1: Spotlight on PTX-100: On the verge of a major inflexion point
For personal use only Spotlight on PTX-100: On the verge of a major inflexion point December 2023
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: Diversified portfolio of later stage and emerging assets
Diversified portfolio of later stage and emerging assets For personal use only Ph1b drug with potential for rapid clinical Targeted development. therapies Encouraging activity in areas of unmet need Cell therapy platform with demonstrated benefits ready for the clinic. Platform with potential to rev
Slide 4: PTX is entering a new stage
PTX is entering a new stage For personal use only 4
Slide 5: PTX-100 Background
For personal use only PTX-100 Background 5
Slide 6: PTX-100 Executive Summary
PTX-100 Executive Summary For personal use only First in Class inhibitor Clinical Status of Ras pathway • Licensed from Yale • Phase 1b trial concluding in r/r TCL • Downstream MoA captures • Excellent safety many Ras mutant variants • Encouraging efficacy vs expected from SoC • PTX-100 is only RhoA
Slide 7: Novel Ras pathway inhibition
Novel Ras pathway inhibition For personal use only GROWTH FACTOR RECEPTOR TYR KINASE Grb2 SoS Ras FGTI PI3K FTI Akt PTX-100 disrupts the Ras pathway by inhibiting the downstream activation of Rheb PTX-100 Ral, Rac and Rho mTOR Rho Rac Ral through prenylation inhibition 7
Slide 8: PTX-100 addresses many types of Ras mutations
PTX-100 addresses many types of Ras mutations For personal use only 3 types of Ras • 80% of cancer Ras cancer patients harbour more than one Ras mutation! • Targeting one particular Ras variant (e.g. KRAS G12C) may lead to relapse driven by resistant clones • PTX-100’s unique MoA, working downstream
Slide 9: PTX-100 is also the only drug targeting RhoA
PTX-100 is also the only drug targeting RhoA For personal use only Schematic of RhoA protein structure, with alterations • Various RhoA mutations drive a number of hematologial and solid malignancies • PTX-100 a pan RhoA inhibitor regardless of mutation • Only clinical stage RhoA inhibitor globally
Slide 10: T-cell lymphomas (TCL)
T-cell lymphomas (TCL) For personal use only • TCL occurs when T-cells undergo changes • TCL represents an area of high unmet need and become cancerous • Poor patient outcomes – even responders often relapse • TCL is 10-15% of all non-Hodgkin lymphomas • New entrants, but outcomes are still poor, •
Slide 11: Drugs in areas of unmet need can command higher prices
Drugs in areas of unmet need can For personal use only command higher prices Case Study • Folotyn (pralatrexate) • Approved 2009 for PTCL • Overall Response Rate was 27% • US $842,585 per patient, per year 11
Slide 12: Advantages of Orphan Drugs
Advantages of Orphan Drugs For personal use only Orphan 11.6% CAGR 7 7 years of guaranteed market exclusivity in US Non-orphan 7% CAGR Consistently higher sales growth Enjoy higher prices than non-orphan drugs Sales are more resilient Total orphan sales to cycles to reach $US300B by 2028 Evaluate Lt
Slide 13: PTX-100 Phase 1b study
For personal use only PTX-100 Phase 1b study 13
Slide 14: PTX-100: Ph1b Clinical Summary
PTX-100: Ph1b Clinical Summary For personal use only • Aims: Phase 1b to evaluate safety PK/PD • Design: Dose escalation in advanced malignancies; expansion cohort in relapsed & refractory T cell lymphomas • Results: • Excellent safety Professor H. Miles Prince, AM • Target engagement at all 3 doses
Slide 15: Strong response rates in difficult diseases
Strong response rates in difficult diseases For personal use only Overall Response Rate Clinical Benefit Rate CR + PR CR + PR + SD>6months Benchmark1 30% 45% r/r PTCL (n=4) 50% (2/4) 50% (2/4) r/r CTCL (n=5) 40% (2/5) 80% (4/5) r/r TCL (n=9) 44% (4/9) 66% (6/9) 1. Considered a target benchmark by Pr
Slide 16: Median Progression Free Survival exceeds expectations
Median Progression Free Survival (mPFS1) exceeds expectations For personal use only mPFS benchmarks in r/r TCL: Standard of care: ~4 months mPFS: mPFS: mPFS: For a registration study: 5-6 months1 12.2 months 13.6 months 7.4 months 1. Progression Free Survival is the time from first treatment until d
Slide 17: r/r TCL swimmer plot: responses and duration
r/r TCL swimmer plot: responses and duration For personal use only SoC Target Enrollment completed but study ongoing; results as at 1 Dec 2023 17
Slide 18: Favourable safety profile compared to peers
Favourable safety profile compared to peers For personal use only Approved PTCL drugs have troublesome safety profiles % Serious Adverse Events (≥Grade 3) PTX-100 HAS AN for Approved PTCL Drugs EXCELLENT SAFETY PROFILE Mogamulizumab • No serious adverse events Chidamide related to PTX-100 Brentuxima
Slide 19: Prescient at ASH Meeting 2023
Prescient at ASH Meeting 2023 For personal use only 19
Slide 20: PTX-100 data at ASH
For personal use only PTX-100 data at ASH • PTX-100 data in TCL was received very positively by industry and KOLs • The nature of PTX-100’s efficacy observations seem unique : • Other TCL drugs only achieve durability when they achieve CR, which is a rare event • By contrast, PTX-100 patients experi
Slide 21: Selected KOL quotes on PTX-100 in r/r TCL
Selected KOL quotes on PTX-100 in r/r TCL For personal use only Overall very positive scientific and clinical feedback! • “This is more than an efficacy signal” • “That swimmers plot looks good…hang on, that’s not weeks; it’s in months! Wow!” • “Safety profile is the stand-out feature and could be t
Slide 22: Moving ahead
For personal use only Moving ahead 22
Slide 23: PTX-100 challenges and path forward
PTX-100 challenges and path forward For personal use only Challenges Going forward • Recruitment challenges in a rare disease, but looking to • Manufacturing underway (current) expand to multiple sites in next study • Quality systems & controls (current, ongoing) • 5 day I.V. dosing schedule is dema
Slide 24: PTX-100 Phase 2 variables for consideration
PTX-100 Phase 2 variables for consideration For personal use only Variable Considerations for PTX • PTCL, CTCL or both? Different diseases with diversity of characteristics; needs and endpoints. Do both Disease simultaneously, or lead in with one, then add an arm? • Activity seen at all doses, but m
Slide 25: What does PTX-100's progress mean for PTX?
What does PTX-100’s progress mean for PTX? For personal use only • PTX is on the verge of a major inflexion point with the start of a Phase 2 study for PTX-100 • Biggest catalyst in company’s history, and the culmination of years of work • Potential for the Phase 2 trial to be a registration study (
Slide 26: PTX is entering a new stage
PTX is entering a new stage For personal use only 26
Slide 27: Summary
For personal use only Summary 27
Slide 28: Major catalysts to work towards next year
Major catalysts to work towards next year Prescient will continue to progress the development of programs across its pipeline. Some notable catalysts to For personal use only work towards include, but are not limited to: Q1 2024 Q2 2024 Q3 2024 Q4 2024 Ph 1b data Manuf. PTX-100 FDA meeting Phase 2 p
Slide 29: Key Messages
3 Key Messages For personal use only Encouraging Ph1b data in TCL 1 PTX-100 • Exceeding SoC expectations in an area of unmet need Aiming for Ph2 registration trial in 2024 Lower risk exposure to cell therapy 2 • Improve existing and emerging cell therapies • Agnostic on cell type and targets 3 ~$19M
Slide 30: Thank you!
For personal use only Thank you! ASX code: PTX www.ptxtherapeutics.com
Prescient Therapeutics — Investor Presentation (December 2023) on 6ix